Methods of treating cancer using modified C-reactive protein

Details Methods of treating cancer using modified C-reactive protein Methods of treating cancer using modified C-reactive protein

1992-04-24

1994-02-01

Schain, Howard E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 21, 530380, A61K 3702

Patent

active

052832384

ABSTRACT:
The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of modified C-reactive protein ("mCRP"). The invention also provides a method of treating cancer in a mammal comprising administering to the mammal mCRP in combination with another agent such as a chemotherapeutic compound, immunoadjuvant, or cytokine. The mCRP may be administered to the mammal in a pharmaceutically-acceptable carrier or in liposomes. The invention further provides a method of identifying cancer cells in a mammal using mCRP as an imaging agent.

REFERENCES:
patent: 4816402 (1989-03-01), Rosen et al.
patent: 4857314 (1989-08-01), O'Connor et al.
Barna et al., Cancer Research, 47:3959-3963 (1987).
Barna et al., Cancer Research, 44:305-310 (1984).
Barna et al., FASEB J., 2274a (1983).
Barna et al., J. Biol. Resp. Mod., 7:483-487 (1988).
Barna et al., FASEB J., 6:1433a (1992).
Bravo et al., J. Rheumatology, 8:291-294 (1981).
Bray et al., Clin. Immunol. Newsletter, 8:137-140 (1987).
Chu et al. , Proc. Amer. Acad. Cancer Res., 28:344a (1987).
Chu et al., Proc. Am. Acad. Cancer Res., 29:371a (1988).
Chu et al., Proc. Am. Acad. Cancer Res., 30:333a (1989).
Chudwin et al., J. Allergy Clin. Immunol., 77:216a (1986).
de Beer et al., J. Immunol. Meth., 50:17-31 (1982).
Deodhar et al., J. Biol. Resp. Modifiers, 1:27-34 (1982).
Deodhar et al., Cleveland Clinic Quarterly, 53:223-234 (1986).
Deodhar et al., Cancer Research, 42:5084-5088 (1982).
Deodhar et al., Proc. Am. Assoc. Cancer Research, 32:404 (1991).
Deodhar et al., FASEB J., 3:831a (1989).
Dixon et al., Scand. J. Rheumatology, 13:39-44 (1984).
Gautam et al., J. Biol. Res. Modifiers, 8:560-569 (1989).
Hawkes et al., Analyt. Biochem., 119:14247 (1982).
Hornung, Proc. Soc. Exp. Biol. Med., 139:1166-1169 (1972).
Hu et al., Biochem., 25:7834-7839 (1986).
Hu et al., J. Biol. Chem., 635:1500-1504 (1988).
Kaplan et al., Meth. Enzymol., 172:393-399 (1989).
Kilpatrick et al., Immunol. Res., 10:43-53 (1991).
Krakoff, CA-A Cancer Journal for Clinicians, 41:264-278 (1991).
Laemmli, Nature, 227:680-685 (1970).
Lei et al., J. Biol. Chem., 260:13377-13383 (1985).
MacDonald et al., Biochem. Biophys. Acta, 1061:297-301 (1991).
Mantzouranis et al., Ped. Res., 18:260a (1984).
McIntosh et al., Cancer Research, 49:1408-1414 (1989).
Oku et al., Biochim. Biophys. Acta, 691:332-340 (1982).
Olson et al., Biochim. Biophys. Acta, 557:9-23 (1979).
Osmand et al., Proc. Natl. Acad. Sciences, U.S.A., 74:739-743 (1977).
Pappas et al., J. Immunol. Meth., 64:205-214 (1983).
Pepys et al., Advances in Immunology, 34:141-212 (1983).
Potempa et al., Mol. Immunol., 20:1165-1175 (1983).
Potempa et al., Mol. Immunol., 24:531-541 (1987).
Potempa et al., Proc. Amer. Acad. Cancer Res., 28:344a (1987).
Potempa et al., FASEB J., 2:731a (1988).
Potempa et al., Protides Biol. Fluids, 34:287-290 (1986).
Potempa et al., Inflammation, 12:391-405 (1988).
Radosevich et al., Cancer Research, 46:5808-5812 (1985).
Rees et al., Fed. Proc., 45:263a (1986).
Rizk et al., Cancer, 58:55-61 (1986).
Samols et al., Biochem. J., 227:759-765 (1985).
Samols et al., Protides Biol. Fluids, 34:263-266 (1986).
Sorenson et al., Experientia, 42:161-162 (1986).
Thomassen et al., FASEB J., 6:1151a (1992).
Thombre et al., Cancer Immunol. Immunother., 16:145-150 (1984).
Tillett and Francis, J. Exp. Med., 52:561-571 (1930).
Volanakis et al., J. Immunol., 113:9-17 (1974).
Volanakis et al., J. Immunol., 126:1820-1825 (1981).
Walker et al., J. Clin. Path., 37:1022-1026 (1984).
Wang et al., J. Biol. Chem., 257:13610-13615 (1982).
Weiss, Clinical and Experimental Metastasis, 7:127-167 (1989).
Whitehead et al., Biochem. J., 266:283-290 (1990).
Woo et al., J. Biol. Chem., 260:13384-13388 (1985).
Wood et al., J. Clin. Invest., 30:616-622 (1951).
Ying et al., J. Immunol., 143:221-28 (1989).
Zahedi et al., Cancer Research, 46:5077-5083 (1986).
Zeller et al., Fed. Proc., 46:1033a (1987).
Barna et al., Proc. Am. Assoc. Cancer Res., 32:273 (1991).
Clark et al., J. Biotechniques, in press (1992).
Crowle, Immunodiffusion, Academic Press, N.Y., Ch. 3 (1973).
Guesdon et al., J. Histochem. Cytochem., 27:1131-39 (1979).
Kendall et al., J. Immunol. Meth., 56:329-39 (1983).
Kirby et al., Liposome Technology, Volume I, Preparation of Liposomes, CRC Press, pp. 19-27 (1984).
Waddell, J. Lab. Clin. Med., 48:311-14 (1956).

Affiliated with

Also associated with

Rating

Methods of treating cancer using modified C-reactive protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating cancer using modified C-reactive protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating cancer using modified C-reactive protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-579915